A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Solid Tumors
Metastatic Solid Tumors

Interventions

DRUG: Oral repotrectinib (TPX-0005)

Sponsor

Turning Point Therapeutics, Inc.

Collaborators

[object Object]